Apollomics, Inc. (APLM)
$
16.73
+1.61 (9.62%)
Key metrics
Financial statements
Free cash flow per share
-26.0902
Market cap
15.5 Million
Price to sales ratio
78.0696
Debt to equity
0.1986
Current ratio
1.3876
Income quality
0.5337
Average inventory
0
ROE
-4.1960
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Apollomics, Inc., a biotechnology company engaged in the discovery and development of oncology therapies, focuses on addressing unmet medical needs across various regions including California, Hangzhou, Shanghai, China, and Australia. The total costs and expenses for the company are $42,334,000.00 reflecting its overall spending. Additionally, the operating expenses amount to $42,334,000.00 which encompass various operational costs incurred in the pursuit of developing its innovative therapies. The gross profit ratio is 1.00 indicating the efficiency of the company's production and sales operations. Furthermore, the company recorded an operating income of -$42,136,000.00 demonstrating its earnings from core operations. The company's stock is identified with the symbol 'APLM' in the market, providing investors with a point of reference when trading or seeking information about the company's performance. In the realm of investment, the stock is affordable at $18.43 making it suitable for budget-conscious investors looking to enter the market. However, it’s noteworthy that the stock has a low average trading volume of 45,668.00 indicating lower market activity which may impact liquidity. With a market capitalization of $18,453,345.00 the company is classified as a small-cap player, suggesting it has unique opportunities and challenges in the competitive investment landscape. Apollomics, Inc. is a key player in the Biotechnology industry, contributing significantly to the overall market landscape through its pioneering therapeutic developments. Additionally, it belongs to the Healthcare sector, driving innovation and growth within its focus area, and highlighting its potential for future advancements in oncology therapies.
Is Apollomics, Inc. (APLM) a good investment?
Investing in Apollomics, Inc. (APLM) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Apollomics, Inc. (APLM)'s stock forecast?
Analysts predict Apollomics, Inc. stock to fluctuate between $3.66 (low) and $42.12 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Apollomics, Inc.'s market capitalization?
As of 2025-12-19, Apollomics, Inc.'s market cap is $18,453,345, based on 1,103,339 outstanding shares.
How does Apollomics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Apollomics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Apollomics, Inc. (APLM) stock?
To buy Apollomics, Inc. (APLM) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for APLM. Place an order (Market, Limit, etc.).
What is the best time to invest in Apollomics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Apollomics, Inc. stock ever split?
Apollomics, Inc.'s last stock split was 1:100 on 2024-11-25.
How did Apollomics, Inc. perform in the last earnings report?
Revenue: $198,000 | EPS: -$52.80 | Growth: -77.24%.
Where can I find Apollomics, Inc.'s investor relations reports?
Visit https://www.apollomicsinc.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Apollomics, Inc.?
You can explore historical data from here
What is the all-time high and low for Apollomics, Inc. stock?
All-time high: $4,900 (2023-03-30) | All-time low: $3.66 (2025-08-29).
What are the key trends affecting Apollomics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
11 hours ago
FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2025 ended June 30, 2025.
globenewswire.com
a month ago
FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, “TWVC”), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the “Cayman Litigation”).
globenewswire.com
a month ago
FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company's board of directors (“Board”) and composition of committees.
globenewswire.com
2 months ago
FOSTER CITY, Calif. , Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, had previously announced that it had filed an application to appeal the delisting notification previously received from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market, LLC ("Nasdaq") and request a hearing before a Nasdaq Hearings Panel to review the Staff's delisting determination.
globenewswire.com
2 months ago
FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, had previously announced that it had filed an application to appeal the delisting notification previously received from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) and request a hearing before a Nasdaq Hearings Panel to review the Staff's delisting determination.
globenewswire.com
2 months ago
NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading will resume in Apollomics Inc. Class A ordinary shares (Nasdaq: APLM) and warrants (Nasdaq: APLMW) at 9:00 a.m. and 9:05 a.m. Eastern Time, respectively, on October 15, 2025. Trading in the company's Class A ordinary shares and warrants was halted on September 17, 2025 at 2:37:17 p.m. Eastern Time.
globenewswire.com
2 months ago
FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update.
globenewswire.com
9 months ago
FOSTER CITY, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the fiscal year ended December 31, 2024, and highlighted clinical updates and business progress.
globenewswire.com
9 months ago
FOSTER CITY, Calif. and TAIPEI, Taiwan, March 31, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, and LaunXP International Co., Ltd., an affiliate of LaunXP Biomedical Co., Ltd. (TWO: 6876) (“LaunXP”), announced today that the parties have entered into an agreement for the development and commercialization in Asia (excluding mainland China, Hong Kong and Macau) (the “LaunXP Territory”) of vebreltinib, Apollomics' proprietary c-Met inhibitor, in combination with an EGFR inhibitor (“EGFRi”) for the treatment of NSCLC. The EGFRi class of targeted kinase inhibitors is currently a foundational targeted therapy for the treatment of NSCLC and other tumor types.
globenewswire.com
a year ago
FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today the results from its Phase 3 bridging trial of uproleselan in China in patients with relapsed or refractory acute myeloid leukemia. The trial did not demonstrate favorable benefit for uproleselan.
See all news
